New pa­per sheds fresh light on Tmu­ni­ty's high-pro­file CAR-T deaths

The in­dus­try-wide ef­fort to push CAR-T ther­a­pies — wild­ly ef­fec­tive in sev­er­al blood can­cers — in­to sol­id tu­mors took a hit last year when Tmu­ni­ty, a biotech found­ed by CAR-T pi­o­neer Carl June and backed by sev­er­al blue-chip VCs, an­nounced it shut down its lead pro­gram for prostate can­cer af­ter two pa­tients died.

Since then, Tmu­ni­ty has gone vir­tu­al­ly dark, los­ing or let­ting go all but one mem­ber of its 6-per­son C-suite, in­clud­ing CEO Oz Azam, and not re­leas­ing a sin­gle press re­lease. The com­pa­ny has al­so yet to pub­lish a de­tailed analy­sis of the prostate can­cer tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER